[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.171.35. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
September 1984

Clinical Trial of a New Trivalent Measles-Mumps-Rubella Vaccine in Young Children

Author Affiliations

From the Department of Clinical Sciences, University of Tampere (Dr Vesikari), the Health Care Center of the City of Tampere (Drs Ala-Laurila, Heikkinen, and Terho), Tampere, Finland, and the Biological Division, Smith Kline RIT, Rixensart, Belgium (Mr D'Hondt and Dr André).

Am J Dis Child. 1984;138(9):843-847. doi:10.1001/archpedi.1984.02140470043013
Abstract

• Trivalent measles-mumps-rubella virus vaccines, containing either Schwarz (two dosage levels), Urabe Am 9, and RA 27/3 strains or Moraten, Jeryl Lynn, and RA 27/3 strains, were evaluated in 174 children aged 14 to 24 months. Each of the three vaccines induced a nearly 100% seroconversion for measles and mumps and a full 100% seroconversion for rubella. Close home monitoring disclosed a high incidence and a relatively constant pattern of vaccine-associated reactions, similar for all three vaccines. Febrile reactions of greater than or equal to 39 °C between days 5 and 12 after vaccination were more frequent among the recipients of "high"-dose Schwarz strain vaccine (35%) than among the recipients of corresponding "low"-dose vaccine (23%) or the Moraten strain vaccine (13%). The Schwarz-Urabe Am 9-RA 27/3 was equally immunogenic and, with a low dose of measles virus, no more reactogenic than the Moraten-Jeryl Lynn RA 27/3 trivalent vaccine.

(AJDC 1984;138:843-847)

×